Salbutamol |
Inhaler |
100 mcg/dose |
SDL |
|
Salbutamol |
Nebulisation solution |
0.5% |
SDL |
|
Salbutamol |
Concentrate for infusion |
5 mg/5 mL |
SDL |
|
Salbutamol |
Oral liquid |
2 mg/5 mL |
SDL |
|
Salbutamol |
Tablet |
2 mg |
SDL |
|
Salicylic Acid |
Cream |
2%, 20% |
SDL |
|
Salicylic Acid |
Ointment |
1%, 2%, 5%, 10%, 20%, 40% |
SDL |
|
Salicylic Acid & Lactic Acid |
Topical solution |
Salicylic Acid 16.7% + Lactic Acid 16.7% Collodion, Salicylic Acid 17% + Lactic Acid 17% Collodion |
SDL |
|
Salmeterol & Fluticasone Propionate |
Inhaler |
Salmeterol 25 mcg/dose + Fluticasone Propionate 50 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 125 mcg/dose, Salmeterol 25 mcg/dose + Fluticasone Propionate 250 mcg/dose |
SDL |
|
Salmeterol & Fluticasone Propionate |
Powder inhaler |
Salmeterol 50 mcg/dose + Fluticasone Propionate 100 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 250 mcg/dose, Salmeterol 50 mcg/dose + Fluticasone Propionate 500 mcg/dose |
SDL |
|
Sea Snake Venom Antiserum |
Concentrate for infusion |
1,000 units/dose |
SDL |
|
Selenium Sulfide |
Topical suspension |
2.5% |
SDL |
|
Sennosides |
Tablet |
7.5 mg |
SDL |
|
Sertraline |
Tablet |
50 mg |
SDL |
|
Sevelamer Carbonate | Tablet | 800 mg | MAF | Treatment of hyperphosphataemia in patients with chronic kidney disease who have persistent hyperphosphataemia despite optimising treatment with calcium-based phosphate binders, or who are unable to tolerate calcium-based phosphate binders due to hypercalcaemia. |
Silicone Cream |
Cream |
Dimethicone 10%, Chlorocresol 0.1% |
SDL |
|
Simeticone |
Oral suspension |
100 mg/mL |
SDL |
|
Simvastatin |
Tablet |
10 mg, 20 mg |
SDL |
|
Sirolimus |
Tablet |
0.5 mg, 1 mg, 2 mg |
MAF |
For kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity |
Sirolimus |
Oral solution |
1 mg/mL |
MAF |
For kidney transplant immunosuppression in patients with:
1) Evidence of CNI-induced nephrotoxicity on allograft biopsy OR
2) Elevated serum creatinine levels precluding the achievement of optimal therapeutic blood levels of CNI OR
3) History of CNI drug hypersensitivity |
Sodium Alginate, Sodium Bicarbonate & Calcium Carbonate |
Oral suspension |
Sodium Alginate 500 mg/10 mL + Sodium Bicarbonate 267 mg/10 mL + Calcium Carbonate 160 mg/10 mL |
SDL |
|
Sodium Bicarbonate |
Infusion |
4.2%, 8.4% |
SDL |
|
Sodium Bicarbonate |
Injection |
4.2%, 8.4% |
SDL |
|
Sodium Bicarbonate |
Capsule |
500 mg |
SDL |
|
Sodium Bicarbonate |
Powder |
Minimum 99% |
SDL |
|
Sodium Bicarbonate & Sodium Chloride |
Powder |
9 parts Sodium Bicarbonate + 1 part Sodium Chloride |
SDL |
|
Sodium Calcium Edetate |
Injection |
200 mg/mL |
SDL |
|
Sodium Chloride |
Infusion |
0.45%, 0.9%, 3%, 20% |
SDL |
|
Sodium Chloride |
Irrigation solution |
0.9% |
SDL |
|
Sodium Chloride |
Injection |
0.45%, 0.9%, 3%, 20% |
SDL |
|
Sodium Chloride |
Eye drops |
0.9%, 5% |
SDL |
|
Sodium Chloride |
Eye ointment |
5% |
SDL |
|
Sodium Chloride & Dextrose |
Sustained-release tablet |
Sodium Chloride 500 mg + Dextrose 200 mg |
SDL |
|
Sodium Chloride, Calcium Chloride Dihydrate & Potassium Chloride |
Infusion |
Sodium Chloride 8.6 g/L + Calcium Chloride Dihydrate 0.33 g/L + Potassium Chloride 0.3 g/L |
SDL |
|
Sodium Laurylsulfoacetate & Sodium Citrate |
Enema |
Sodium Laurylsulfoacetate 9 mg/mL + Sodium Citrate 90 mg/mL + Sorbitol 625 mg/mL |
SDL |
|
Sodium Nitrite |
Injection |
3% |
SDL |
|
Sodium Nitroprusside |
Injection |
10 mg/mL, 50mg/2ml |
SDL |
|
Sodium Polystyrene Sulfonate |
Oral suspension |
15 g/60 mL |
SDL |
|
Sodium Polystyrene Sulfonate |
Powder for oral suspension |
99% |
SDL |
|
Sodium Tetradecyl Sulfate |
Injection |
1%, 3% |
SDL |
|
Sodium Thiosulfate |
Injection |
25% |
SDL |
|
Sodium Thiosulfate |
Oral solution |
25% |
SDL |
|
Sodium Thiosulfate |
Powder |
50 g |
SDL |
|
Sodium Valproate |
Controlled-release tablet |
200 mg, 300 mg, 500 mg |
SDL |
|
Sodium Valproate |
Enteric-coated tablet |
200 mg |
SDL |
|
Sodium Valproate |
Injection |
400 mg |
SDL |
|
Sodium Valproate |
Syrup |
200 mg/5 mL |
SDL |
|
Sofosbuvir & Velpatasvir | Tablet | Sofosbuvir 400 mg + Velpatasvir 100 mg | MAF | Checklist to be completed. Treatment of chronic hepatitis C infection (all genotypes) in treatment-naïve, or pegylated interferon plus ribavirin (PR)-experienced or NS3/4A protease inhibitor (boceprevir, simeprevir, telaprevir)-experienced adults.
Sofosbuvir/velpatasvir should be used in line with the recommended treatment regimen and duration: • 12 weeks’ treatment of sofosbuvir/velpatasvir for patients with hepatitis C virus (all genotypes) without cirrhosis or with compensated cirrhosis (Child-Pugh A). For patients with genotype 3, the addition of ribavirin may be considered in patients who are treatment-experienced or have compensated cirrhosis (Child-Pugh A). • 12 weeks’ treatment of sofosbuvir/velpatasvir in combination with ribavirin for patients with hepatitis C virus (all genotypes) with decompensated cirrhosis (Child-Pugh B or C). |
Solifenacin Succinate | Tablet | 5 mg | SDL | |
Somatostatin (as Acetate) |
Infusion |
3 mg |
SDL |
|
Somatropin |
Prefilled pen |
5 mg/1.5 mL, 10 mg/1.5 mL |
MAF |
Treatment of children with short stature due to conditions associated with growth failure
*Somatropin is not recommended for the treatment of idiopathic short stature |
Somatropin |
Injection |
3.33 mg, 4 mg, 6 mg |
MAF |
Treatment of children with short stature due to conditions associated with growth failure
*Somatropin is not recommended for the treatment of idiopathic short stature |
Spironolactone |
Tablet |
25 mg |
SDL |
|
Streptokinase |
Infusion |
1.5 million international units |
SDL |
|
Streptomycin |
Injection |
1 g, 5 g |
SDL |
|
Sulfadiazine Silver |
Cream |
1% |
SDL |
|
Sulfamethoxazole & Trimethoprim |
Concentrate for infusion |
Sulfamethoxazole 80 mg/mL + Trimethoprim 16 mg/mL |
SDL |
|
Sulfamethoxazole & Trimethoprim |
Suspension |
Trimethoprim 40 mg/5 mL + Sulphamethoxazole 200 mg/5 mL |
SDL |
|
Sulfamethoxazole & Trimethoprim |
Tablet |
Trimethoprim 20 mg + Sulphamethoxazole 100 mg, Trimethoprim 80 mg + Sulphamethoxazole 400 mg |
SDL |
|
Sulfasalazine |
Enteric-coated tablet |
500 mg |
SDL |
|
Sulphur & Salicylic Acid |
Cream |
Sulphur 4% + Salicylic Acid 2% |
SDL |
|
Sulphur, Resorcinol & Calamine |
Lotion |
Sulphur 4% + Resorcinol 2% + Calamine 10% |
SDL |
|
Sulphur, Zinc Oxide, Resorcinol & Calamine |
Cream |
Sulphur 4% + Zinc Oxide 8% + Resorcinol 2% + Calamine 8% |
SDL |
|
Sulpiride |
Tablet |
200 mg |
SDL |
|
Sumatriptan |
Tablet |
50 mg |
SDL |
|
Suxamethonium Chloride |
Injection |
50 mg/mL |
SDL |
|